RT Journal Article
SR Electronic
T1 A Higher Body Mass Index and Fat Mass Are Factors Predictive of Docetaxel Dose Intensity
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5655
OP 5662
VO 33
IS 12
A1 SOPHIE GOUÉRANT
A1 MARIANNE LEHEURTEUR
A1 MAHER CHAKER
A1 ROMAIN MODZELEWSKI
A1 OLIVIER RIGAL
A1 CORINNE VEYRET
A1 GÉRALDINE LAURIDANT
A1 FLORIAN CLATOT
YR 2013
UL http://ar.iiarjournals.org/content/33/12/5655.abstract
AB Background: Few data are published on docetaxel toxicity in obese patients. Patients and Methods: All obese patients (n=100) treated for early breast cancer during three consecutive years at our Institution, were retrospectively investigated. The same number of non-obese patients was randomly selected and used as controls. We assessed the factors predictive of the relative dose intesity (RDI) reduction, including body composition. Results: A total of 18% (n=18) of obese patients and 5% (n=5) of non-obese patients required reduction of docetaxel RDI due to toxicity (p=0.008). In a multivariate analysis, body mass index (BMI) and age were predictive of a reduction in RDI. Among the 89 patients with a determination of body composition, patients with a higher fat mass more frequently had a reduction in docetaxel RDI (p=0.002). In multivariate analysis, fat mass was the only independent factor predictive of a reduction in docetaxel RDI. Conclusion: Obese patients treated for early breast cancer more frequently required a reduction in docetaxel RDI. Fat mass seems to be the best factor predictive of a reduction in docetaxel RDI.